Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models ...

In the randomized dose-expansion phase of a Phase 1 study (NCT03460977), the combination of mevrometostat (1250 mg twice daily on an empty stomach) and enzalutamide (160 mg once daily) demonstrated ...

This article dives into the 781 area code, taking a closer look at its importance, and whether receiving calls from this area should be seen as a good thing ...

COCOON dermatologic management lessened skin side effects and improved quality of life versus standard care for patients with ...

Dr. Alan Bryce presented the preliminary results from a phase II trial of PT-112 monotherapy in late-line metastatic castration-resistant prostate cancer (mCRPC). Late-line mCRPC patients have poor ...

BioAtla (BCAB) announced data in a poster titled, “Phase 2 Trial of Ozuriftamab Vedotin, a Conditionally Binding CAB-ROR2-ADC, in Patients with ...

I was in Chicago this weekend attending the ASCO meeting, the largest oncology meeting in the world. Nary a talk or poster about "turbo cancer" was seen, but that doesn't mean there wasn't cancer quac ...

J INTS BIO, a company specializing in the development of therapeutics for cancer and rare diseases, officially announced ...